X

Biologics Community

The Biologics Community is dedicated to advancing the development and clinical use of biologic therapies by applying key principles of clinical pharmacology and translational medicine. Through this focus, the Community aims to bridge the gap between research and patient care, ensuring that biologic treatments are effectively developed, tested, and applied in clinical settings.

Community Goals 

Scientific Expertise
The Biologics Community serves as a key resource for best practices in clinical pharmacology related to biologic therapies. Through ASCPT Annual Meeting programming and ongoing educational initiatives, the community provides valuable insights, guidance, and learning opportunities to support the safe and effective use of biologic drugs. These efforts ensure that members stay informed on the latest developments and innovations in the field.
Catalyst for Innovation
Identifies ‘disruptive’ approaches and new modalities of biologic drugs (monoclonal antibody, antibody-drug conjugate, bispecific antibodies, etc.) that challenge traditional perspectives in Clinical Pharmacology. By highlighting these innovations, the community fosters the exchange of groundbreaking ideas within ASCPT and among its members.
Influence and Impact
Builds and nurtures strong partnerships with other ASCPT communities and complementary organizations to drive impactful discussions. By staying at the forefront of current issues affecting biologic therapies, we position the community as recognized thought leaders, shaping the conversation on innovations and best practices in the field.
Education and Communication
The Biologics Community is actively creating educational resources (symposiums, manuscripts, webinars, podcasts, special issues …etc.) that highlight the unique characteristics of biologic drug therapies. These materials also aim to address key clinical pharmacology considerations to ensure their safe and effective use, helping to advance understanding and best practices of biologic treatments.
Organizational Effectiveness
The Biologics Community has formed a dedicated Steering Committee, with clear roles and expectations designed to ensure alignment with the broader goals of the Community. In addition to strategic guidance, the committee fosters ongoing engagement through consistent communication with members, sharing key updates, opportunities for collaboration and announcements. This outreach also recognizes and celebrates the invaluable contributions of volunteers and members, whose efforts drive the success of the Community’s events and initiatives.

Join the LinkedIn Group.

 
Past Webinars:
The webinars below can be accessed in the Members Only Webinar Library: Access Library
  • The US Food & Drug Administration's Perspective on Immunogenicity
  • Quantitative Clinical Pharmacology Approaches Towards Understanding Exposure and Response of CAR-T Cell Therapies
  • Product to Patient Translation of Cell Therapies: Opportunities & Challenges for MIDD
  • Development of Talimogene Laherparepvec, First FDA Approved Genetically Modified Oncolytic Virus: Perspectives of Clinical Pharmacology
  • Considerations in the Design and Development of T-cell Dependent Bispecific Antibodies for Cancer Immunotherapy
  • Mechanistic Models of the Immune System for Quantitative Prediction and Simulation of Biotherapeutic Immunogenicity
  • Role of PK/PD Assessments at the Site of Action in Decision Making during the Development of Monoclonal Antibodies: Examples and Case Studies
Junyi Li

Junyi Li, PhD

Community Chair
Sihem Bihorel

Sihem Bihorel, PhD

Community Vice Chair
J Chen

Joseph Chen, PharmD

Community Co-Past Chair
A Singh

Aman Singh, PhD

Community Co-Past Chair
<

Steering Committee Members

Aruna Dontabhaktuni, PhD
Ganesh Mugundu, PhD
Devam Desai, PhD
Qin Sun, PhD
Sharad Sharma, PhD
Songmao Zheng, PhD
Tao Long, PhD
Yang Zhao, PhD
Yow-Ming Wang, PhD
Tu Mai, PhD
Yan Xu, PhD
Photo Gallery
Recent News
Contact Us